Mylan has announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Efavirenz...
Mylan agreed to pay $96.5 million to a group of drug purchasers to settle allegations made in 2006 that the company paid Cephalon to delay the launch of a generic version of the narcolepsy therapy Provigil (modafinil).
Mylan and Biocon Ltd. have announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, for filing through the 351(k) pathway. This product is a propo